We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Max P. Horowitz is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 2010 — 2013 |
Horowitz, Max Parven |
F30Activity Code Description:
Individual fellowships for predoctoral training which leads to the combined M.D./Ph.D. degrees. |
Gata2 as a Therapeutic Target in Parkinson's Disease @ University of Pittsburgh At Pittsburgh
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is associated with pathological increases in iron and 1-synuclein (1-syn) in the substantia nigra (SN), and these features are reproduced animal models of PD that use the pesticide rotenone. Both 1-syn and iron accumulate in nigral dopamine neurons and are cytotoxic;however, the mechanism underlying their pathological accumulation is unknown. We have identified a transferrin/transferrin receptor 2 (TfR2)-mediated mechanism for iron accumulation in nigral dopamine neurons, and have found that TfR2 levels are increased in dopamine neurons in the rotenone rat. GATA transcription factors, whose role has been well characterized in hematopoiesis, have recently been shown to positively regulate the expression of 1-syn in vitro. The isoform GATA2 is expressed in human SN, and preliminary studies have localized GATA2 to dopamine neurons in rat SN. Preliminary data indicate that GATA2 positively regulates TfR2 transcription in vitro. Thus it is possible that GATA2 positively and coordinately regulates both 1-syn and TfR2 in nigral dopamine neurons in vivo, and that therapeutic GATA2 inhibition may simultaneously ameliorate the deleterious effects of both 1-syn and iron in PD. This proposal will use in vivo viral-mediated gene silencing in rat SN to test the following hypotheses: 1) GATA2 regulates 1-syn and TfR2 in rat nigral dopamine neurons, and 2) inhibition of GATA2 in nigral dopamine neurons leads to decreased accumulation of 1-syn and iron following rotenone treatment, thereby attenuating nigrostriatal degeneration. This work will examine how two apparently disparate pathological features of PD-the accumulation of 1-synuclein and the accumulation of iron within nigral dopamine neurons-may be coordinately attenuated via inhibition of the transcription factor, GATA2, using in vivo viral-mediated gene silencing. Successful completion of these aims would establish GATA2 as a potential therapeutic target that could be exploited using gene therapy to ameliorate the cellular toxicity associated with both 1-syn and iron accumulation in human PD. PUBLIC HEALTH RELEVANCE: Parkinson's disease (PD) is a neurodegenerative disorder that affects over one million Americans and currently no therapies alter disease progression. This research will evaluate whether a specific gene therapy intervention prevents brain degeneration by simultaneously acting on two important pathological features of the disease. A novel therapeutic intervention for eventual clinical use in human PD may be identified through this work, thereby addressing a major public health burden.
|
1 |